Skip Navigation Links
 Venue 
 تاریخ های مهم 
 Registration 
 Pre Registered 
 Abstracts 
 برنامه همایش 
 Exhibition 
 Personal page 
  
 Archive 
                             دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد        شب بهاری چشم پزشکی با رحیم شهریاری       دومین همایش بهاره چشم پزشکی
Skip Navigation Links
        مکان برگزاری
        تاریخ های مهم
        ثبت نام
        ثبت نام شدگان
        مقالات
        برنامه همایش
        نمایشگاه
        صفحه شخصی
        جستجوی سخنران
        آرشیو
 
مقاله Abstract


Title: Single-Chain Fragment VEGF Antibody (HR6) effects as an inhibitor on Choroidal Neovascularization
Author(s): Zinat Mohammadi, Narsis Daftarian, Masoumeh Rajabibazl, Mozhgan Rezaei Kanavi
Presentation Type: Poster
Subject: Physiology/Pharmacology
Others:
Presenting Author:
Name: Narsis Daftarian
Affiliation :(optional) Ocular Tissue Engineering Research Center,SBMU, Tehran, Iran
E mail: nardaftarian@hotmail.com
Phone: 88772113
Mobile: 09126162204
Purpose:

Evaluation the effect of single chain variable fragment antibody (scFv) in inhibition of angiogenesis in an animal model of laser induced choroidal neovascularization(CNV)

Methods:

In this study, a recombinant single-chain antibody (HR6) was derived from Tomlinson(i+j) phage display library, transferred and expressed in non-suppressor HB2151 bacteria. HR6 was purified by NI-NTA affinity chromographyand analyzed with Westernblot technique. In vivo assays were designed in 2 phases. In phase ǀ, to test retinal toxicity, fifteen, 6-8 old weeks male c57bl6 mice, were divided in 3 groups. Each group received intravitreal HR6 injection of 0.5 μg, 1μg and 1.5 μg/1 μl, respectively. Ophthalmic examination and electroretinography (ERG) were performed after 7 and 28 days. In phase ǁ, CNV was induced via laser burns in right eyes of 25 mice. The animals were divided into control and treatment groups. Three of which received the same HR6 doses of ERG assay, one group received bevacizumab as positive control the same dose as clinical use and another group received PBS intravitrealy. Two weeks later, CNV scores were detected in sclerochoroidal flatmounts, stained with antibodies against intercellular adhesion molecule-2. CNV area were measured using flurosence microscopy and image j software.

Results:

In phase 1, ERG results were unremarkable in terms of retinal toxicity in treatment and control groups. The flat mount analysis have shown significant reduction of formation the new blood vessels compared to control group in three different doses of intravitreal injection of HR6 antibody (p? o.oo1).

Conclusion:

HR6 as a scFv antibody, because of its small size compared to complete antibody as Bevacizumab, improve tissue penetration and lower immunogenicity. In this study we showed that intravitreal injection of up to 1.5 μg/1 of this antibody has no toxicity on retina and is effective to reduce laser induced choroidal neovascularization.

Attachment: 44Poster for IRAVO 2018.pptx





Last News

  - دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد
  -  شب بهاری چشم پزشکی با رحیم شهریاری
  - دومین همایش بهاره چشم پزشکی